Sector News

Sanofi signs agreement to acquire Kiadis Pharma for $359m

November 6, 2020
Life sciences

Sanofi has signed a definitive agreement to acquire the entire share capital of Kiadis Pharma in a deal valued at approximately €308m ($359m).

Under the agreement, Sanofi will offer €5.45 per share to Kiadis Pharma, a clinical-stage company developing cell-based immunotherapy products.

The acquisition will give Sanofi full control of next-generation natural killer (K-NK) cell platform and pipeline of cell-based cancer immune-therapeutics and infectious disease treatments.

The K-NK cell platform derives from allogeneic or ‘off-the-shelf’ NK cells from a healthy donor and these cells hunt for malignant cancer cells.

It can potentially make products rapidly and economically available for a broad range of indications.

Under the deal, Kiadis will develop NK cell-based medicines alone or with Sanofi’s existing platforms.

Furthermore, the research, development and commercial expertise of Sanofi will be leveraged to advance Kiadis’ pipeline that includes NK cell-based medicines.

Sanofi Research & Development global head John Reed said: “We believe the Kiadis ‘off the shelf’ K-NK cell technology platform will have broad application against liquid and solid tumours, and create synergies with Sanofi’s emerging immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches.”

On completion of the public offer, Sanofi will provide the resources and capabilities needed for boosting the development of Kiadis’ programmes.

Kiadis’ pipeline of NK cell therapies includes K-NK002, K-NK003 and KNK-ID-101.

KNK-ID-101 is a programme analysing the properties of K-NK cells and their suitability to fight SARS-CoV-2. It will also analyse whether the cells can be used as a post-exposure pre-emptive therapy for Covid-19 in high-risk patients.

The company anticipates initiating a Phase I / IIa trial evaluating the use of K-NK cells to treat covid-19 patients with government grant funding.

In July, the company licensed Kiadis’ pre-clinical K-NK004 programme for potential combination for multiple myeloma.

by Pharmeceutical-technology.com

Source: pharmaceutical-technology.com

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend